Celgene Corporation Company Profile (NASDAQ:CELG)

About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CELG
  • CUSIP: 15102010
  • Web: www.celgene.com
  • Market Cap: $107.56 billion
  • Outstanding Shares: 780,824,000
Average Prices:
  • 50 Day Moving Avg: $128.98
  • 200 Day Moving Avg: $122.58
  • 52 Week Range: $96.93 - $138.93
  • Trailing P/E Ratio: 51.24
  • Foreward P/E Ratio: 15.62
  • P/E Growth: 0.91
Sales & Book Value:
  • Annual Revenue: $11.68 billion
  • Price / Sales: 9.21
  • Book Value: $9.79 per share
  • Price / Book: 14.07
  • EBIDTA: $4.11 billion
  • Net Margins: 18.32%
  • Return on Equity: 70.94%
  • Return on Assets: 16.37%
  • Debt-to-Equity Ratio: 1.80%
  • Current Ratio: 4.42%
  • Quick Ratio: 4.23%
  • Average Volume: 3.98 million shs.
  • Beta: 1.89
  • Short Ratio: 2.24
Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)

What is Celgene Corporation's stock symbol?

Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?

Celgene Corporation's stock split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.

How were Celgene Corporation's earnings last quarter?

Celgene Corporation (NASDAQ:CELG) announced its quarterly earnings data on Thursday, April, 27th. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.21. The business earned $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The company's revenue was up 17.8% on a year-over-year basis. During the same period last year, the business earned $1.32 earnings per share. View Celgene Corporation's Earnings History.

When will Celgene Corporation make its next earnings announcement?

Celgene Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Celgene Corporation.

What guidance has Celgene Corporation issued on next quarter's earnings?

Celgene Corporation updated its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $7.15-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.21. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.26 billion.

Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?

26 equities research analysts have issued 1-year price targets for Celgene Corporation's stock. Their predictions range from $98.00 to $162.00. On average, they expect Celgene Corporation's stock price to reach $141.27 in the next twelve months. View Analyst Ratings for Celgene Corporation.

What are analysts saying about Celgene Corporation stock?

Here are some recent quotes from research analysts about Celgene Corporation stock:

  • 1. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration. Celgene continues to progress with its label expansion efforts and pipeline development. Revlimid was approved as a single agent for maintenance therapy in adult patients with NDMM following ASCT both in the U.S. and EU. Celgene’s NDA for Idhifa for relapsed and/or refractory acute myeloid leukemia was granted Priority Review with a PDUFA action date of Aug 30, 2017. Label expansion of drugs would boost revenues significantly. Moreover, shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid. Otezla sales in the first quarter were impacted by managed care dynamics that drove lower total marketplace prescriptions for psoriasis therapies although the pressure should ease as the year goes." (7/19/2017)
  • 2. Cantor Fitzgerald analysts commented, "Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts." (7/6/2017)
  • 3. Cann analysts commented, "The 2017 American Society of Clinical Oncology Meeting provided a venue for data presentations for a number of Celgene’s partnered programs, including enasidenib, BMCA CAR-T and JARCAR 017. Celgene had data on its wholly owned products, Revlimid and Abraxane." (6/7/2017)

Who are some of Celgene Corporation's key competitors?

Who are Celgene Corporation's key executives?

Celgene Corporation's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board
  • Scott A. Smith, President, Chief Operating Officer
  • Mark J. Alles, Chief Executive Officer, Director
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President
  • Terrie Curran, President, Global Inflammation & Immunology Franchise
  • Michael F. Pehl, President, Hematology & Oncology
  • Rupert J. Vessey, President - Research and Early Development
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
  • Michael D. Casey, Lead Independent Director
  • Michael W. Bonney, Director

Who owns Celgene Corporation stock?

Celgene Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.43%), Swedbank (0.33%), NN Investment Partners Holdings N.V. (0.15%), Strs Ohio (0.11%), KAMES CAPITAL plc (0.10%) and AMF Pensionsforsakring AB (0.10%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin and Rupert Vessey. View Institutional Ownership Trends for Celgene Corporation.

Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?

Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Strs Ohio, Personal Capital Advisors Corp, Bedrijfstakpensioenfonds Voor DE Media PNO, PGGM Investments, Moody Lynn & Lieberson LLC, Exxonmobil Investment Management Inc. TX and Sumitomo Mitsui Asset Management Company LTD. Company insiders that have sold Celgene Corporation stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene Corporation.

Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?

Celgene Corporation's stock was acquired by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., First Quadrant L P CA, Mn Services Vermogensbeheer B.V., Bank of Montreal Can, Hellman Jordan Management Co. Inc. MA, Fisher Asset Management LLC, OLD National Bancorp IN and Russell Investments Group Ltd.. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.

How do I buy Celgene Corporation stock?

Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene Corporation's stock price today?

One share of Celgene Corporation stock can currently be purchased for approximately $137.75.

MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)
Community Ranking:  4.0 out of 5 (   )
Outperform Votes:  1,508 (Vote Outperform)
Underperform Votes:  359 (Vote Underperform)
Total Votes:  1,867
MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 20 Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $141.27 (2.55% upside)

Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Robert W. BairdReiterated RatingOutperform$162.00LowView Rating Details
7/14/2017SunTrust Banks, Inc.Reiterated RatingBuy$150.00LowView Rating Details
7/11/2017Jefferies Group LLCReiterated RatingBuy -> Buy$160.00LowView Rating Details
7/10/2017Bank of America CorporationReiterated RatingBuy$153.00LowView Rating Details
7/6/2017Credit Suisse GroupSet Price TargetBuy$148.00LowView Rating Details
7/6/2017Stifel NicolausReiterated RatingBuy$139.00LowView Rating Details
7/6/2017Cantor FitzgeraldSet Price TargetBuy$160.00LowView Rating Details
6/30/2017BTIG ResearchDowngradeBuy -> Neutral$96.93 -> $131.70LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$148.00LowView Rating Details
6/7/2017CannReiterated RatingBuyLowView Rating Details
6/6/2017Canaccord GenuitySet Price TargetBuy$156.00LowView Rating Details
6/1/2017MizuhoBoost Price TargetBuy -> Buy$130.00 -> $134.00MediumView Rating Details
5/24/2017J P Morgan Chase & CoReiterated RatingBuyLowView Rating Details
5/23/2017BMO Capital MarketsReiterated RatingOutperform$152.00MediumView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell$93.00 -> $98.00LowView Rating Details
5/5/2017ArgusDowngradeBuy -> Hold$123.91 -> $124.46MediumView Rating Details
4/23/2017Barclays PLCReiterated RatingEqual Weight$120.00 -> $125.00LowView Rating Details
3/8/2017Cowen and CompanyReiterated RatingOutperform$150.00LowView Rating Details
1/27/2017Morgan StanleyLower Price TargetEqual Weight$120.00 -> $117.00N/AView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
12/4/2016Royal Bank Of CanadaReiterated RatingOutperformN/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
10/18/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
9/29/2016Citigroup Inc.Boost Price TargetBuy$124.00 -> $127.00N/AView Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00N/AView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyN/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralN/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Celgene Corporation (NASDAQ:CELG)
Earnings by Quarter for Celgene Corporation (NASDAQ:CELG)
Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20173$1.61$1.68$1.64
Q3 20173$1.68$1.77$1.72
Q4 20173$1.72$1.84$1.78
(Data provided by Zacks Investment Research)


Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)
Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 78.39%
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.00View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.00View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.80View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.50View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.30View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
reuters.com logoCelgene to pay $280 million to settle off-label marketing case
www.reuters.com - July 26 at 3:01 AM
cnbc.com logoCelgene to pay $280 million to settle off-label promotion case
www.cnbc.com - July 26 at 3:01 AM
latimes.com logoCelgene agrees to pay $280 million to settle cancer drug fraud suit
www.latimes.com - July 26 at 3:01 AM
wsj.com logoCelgene Settles Lawsuit Over Improper Promotion of Cancer Drugs
www.wsj.com - July 26 at 3:01 AM
finance.yahoo.com logoCelgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses
finance.yahoo.com - July 26 at 3:01 AM
finance.yahoo.com logo[$$] Celgene Settles Lawsuit Over Improper Promotion of Cancer Drugs
finance.yahoo.com - July 26 at 3:01 AM
finance.yahoo.com logoPharmaceutical company Celgene settles suit for $280 million
finance.yahoo.com - July 26 at 3:01 AM
abcnews.go.com logoCelgene Corp. to pay $280M to settle cancer drug fraud suit - ABC News
abcnews.go.com - July 25 at 10:00 PM
marketbeat.com logoBusiness Highlights
marketbeat.com - July 25 at 5:58 PM
marketbeat.com logoCelgene Corp. to pay $280M to settle cancer drug fraud suit
marketbeat.com - July 25 at 5:15 PM
nasdaq.com logoCelgene To Pay $280 Mln To Resolve False Claims Act Litigation - Quick Facts
www.nasdaq.com - July 25 at 4:59 PM
finance.yahoo.com logoRisk-On Attitude Drive Stocks and Biotech Higher
finance.yahoo.com - July 25 at 4:59 PM
finance.yahoo.com logoCelgene Settles Whistle-Blower Fraud Suit for $280 Million
finance.yahoo.com - July 25 at 4:58 PM
finance.yahoo.com logoCelgene Settles 'Whistle Blower' Lawsuit for $280 Million
finance.yahoo.com - July 25 at 4:58 PM
finance.yahoo.com logoCelgene Corporation Announces Settlement of Civil Litigation
finance.yahoo.com - July 25 at 4:58 PM
finance.yahoo.com logoCelgene to pay $280 mln to settle off-label marketing case
finance.yahoo.com - July 25 at 4:58 PM
nasdaq.com logoIs Celgene (CELG) Poised For a Beat This Earnings Season? - Nasdaq
www.nasdaq.com - July 24 at 11:47 AM
fool.com logoThe case for Gilead Sciences - Motley Fool
www.fool.com - July 24 at 11:47 AM
finance.yahoo.com logoIs Celgene (CELG) Poised For a Beat This Earnings Season?
finance.yahoo.com - July 24 at 11:47 AM
finance.yahoo.com logoNothing Can Keep Celgene Down
finance.yahoo.com - July 23 at 4:41 PM
seekingalpha.com logoPremarket analyst action - healthcare - Celgene Corporation ... - Seeking Alpha
seekingalpha.com - July 21 at 6:43 PM
americanbankingnews.com logoCelgene Corporation (CELG) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 4:59 PM
americanbankingnews.com logoCelgene Corporation (CELG) Earns Outperform Rating from Robert W. Baird
www.americanbankingnews.com - July 21 at 3:34 PM
finance.yahoo.com logoThe Best Stock in New Jersey: Celgene
finance.yahoo.com - July 20 at 6:50 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Apple, JPMorgan, Celgene, PayPal and Vertex Pharmaceuticals
finance.yahoo.com - July 19 at 6:12 PM
americanbankingnews.com logoCelgene Corporation (CELG) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 19 at 1:06 PM
americanbankingnews.com logoQ4 2017 EPS Estimates for Celgene Corporation Lifted by Analyst (CELG)
www.americanbankingnews.com - July 19 at 12:38 PM
fool.com logo3 Big Pharma Companies With the Best Projected Return on Investment
www.fool.com - July 19 at 10:07 AM
americanbankingnews.com logoLeerink Swann Weighs in on Celgene Corporation's Q2 2017 Earnings (NASDAQ:CELG)
www.americanbankingnews.com - July 18 at 10:49 AM
seekingalpha.com logoBetting On The CAR-T Race - Seeking Alpha
seekingalpha.com - July 17 at 5:29 PM
fool.com logoBetter Buy: Biogen Inc. vs. Celgene Corporation - Motley Fool
www.fool.com - July 17 at 5:29 PM
investorplace.com logo5 Pharma and Biotech Stocks Set for Big Q2 Earnings Wins
investorplace.com - July 17 at 7:36 AM
americanbankingnews.com logoVetr Inc. Lowers Celgene Corporation (NASDAQ:CELG) to Buy
www.americanbankingnews.com - July 16 at 12:26 PM
americanbankingnews.com logoStock Traders Buy Large Volume of Call Options on Celgene Corporation (CELG)
www.americanbankingnews.com - July 16 at 7:07 AM
americanbankingnews.com logoCelgene Corporation (NASDAQ:CELG) Expected to Announce Quarterly Sales of $3.23 Billion
www.americanbankingnews.com - July 15 at 9:05 AM
thestreet.com logoThese Are the Best Growth Stocks Right Now in Biotech - TheStreet.com
www.thestreet.com - July 15 at 12:06 AM
americanbankingnews.com logoCelgene Corporation's (NASDAQ:CELG) "Buy" Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - July 14 at 12:42 PM
finance.yahoo.com logoMainStay Mutual Fund Enjoying Big Rally, With Stocks Like Alibaba
finance.yahoo.com - July 13 at 6:06 PM
americanbankingnews.com logo$1.61 EPS Expected for Celgene Corporation (CELG) This Quarter
www.americanbankingnews.com - July 13 at 10:49 AM
americanbankingnews.com logoCelgene Corporation (CELG) Expected to Earn Q2 2017 Earnings of $1.61 Per Share
www.americanbankingnews.com - July 13 at 10:02 AM
nasdaq.com logoPortland Global Advisors LLC Buys Celgene Corp, Sells Mobileye NV, The Kroger Co
www.nasdaq.com - July 12 at 5:40 PM
finance.yahoo.com logoWhy Celgene Corporation Stock Bolted Higher in June
finance.yahoo.com - July 12 at 5:40 PM
finance.yahoo.com logoHow Celgene Stock Performed in 2Q17
finance.yahoo.com - July 12 at 5:40 PM
finance.yahoo.com logoCelgene Price Increases Could Add 3 Cents In EPS This Year
finance.yahoo.com - July 12 at 5:39 PM
fool.com logoWhy Celgene Corporation Stock Bolted Higher in June - Motley Fool
www.fool.com - July 11 at 6:03 PM
fool.com logo3 Top Healthcare Stocks to Buy Today
www.fool.com - July 11 at 5:58 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Celgene Corporation (NASDAQ:CELG)
www.americanbankingnews.com - July 11 at 8:59 AM
americanbankingnews.com logoCelgene Corporation (NASDAQ:CELG) Rating Reiterated by Bank of America Corporation
www.americanbankingnews.com - July 10 at 9:40 PM
fool.com logoBetter Buy: Amgen Inc. vs. Celgene Corporation - Motley Fool
www.fool.com - July 10 at 7:05 AM
fool.com logoBillions of Dollars on the Line for Celgene With These 3 Small Biotechs
www.fool.com - July 9 at 8:23 AM



Celgene Corporation (CELG) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff